$ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Healthcare
Sector
Biotechnology
Industry
Todd Franklin Watanabe
CEO
342
Employees
$25.83
Current Price
$3.27B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $394,896.77 | 15,000 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $566,222.98 | 21,560 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 5 | $566,222.98 | 21,560 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 7 | $709,807.73 | 26,925 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 9 | $930,375.16 | 35,967 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Burnett Patrick Reporting Person's title: EVP, Chief Medical Officer | Sale | 8,300 | $26.52 | $220,129.28 | View Details |
| Aug 12, 2026 | Burnett Patrick Reporting Person's title: EVP, Chief Medical Officer | Sale | 6,700 | $26.08 | $174,767.49 | View Details |
| Aug 3, 2026 | Burnett Patrick Reporting Person's title: EVP, Chief Medical Officer | Sale | 955 | $26.12 | $24,941.54 | View Details |
| Aug 3, 2026 | Matsuda Masaru Reporting Person's title: EVP, Chief Legal Officer | Sale | 1,230 | $26.12 | $32,123.66 | View Details |
| Aug 3, 2026 | Watanabe Todd Director | Sale | 4,375 | $26.12 | $114,261.00 | View Details |
| Jul 15, 2026 | Welgus Howard G. Director | Sale | 4,730 | $26.91 | $127,284.30 | View Details |
| Jun 15, 2026 | LIN SUE-JEAN Director | Sale | 4,946 | $24.38 | $120,586.94 | View Details |
| Jun 15, 2026 | Welgus Howard G. Director | Sale | 4,096 | $24.41 | $99,980.49 | View Details |
| Jun 17, 2026 | Welgus Howard G. Director | Sale | 635 | $25.67 | $16,300.45 | View Details |
73 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: